Stock Analysis of Iterum Therapeutics PLC (ITRM) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ITRM
Close 1.50
Change 0.210 / 16.28 %
Volume 332066
Vol Change 265088 / 395.78 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Iterum Therapeutics PLC
PE (TTM)

-136.84

Very Poor
Price / Book

1435.08

Very Poor
Price / Sales

1858.49

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

24832.35 K

Enterprise Value

38082.35 K

ROA (TTM)

-91.35

Very Poor
ROE (TTM)

-1048.72

Very Poor
Net Margin (TTM)

-1358.13

Very Poor
Revenue

%

0
Net Profit

30.01 %

-31099.00 K
Debt to Equity

-3.02

Very Poor
Altman Z Score

-27.38

Very Poor
Quick Ratio

0

Poor
Cash Ratio

1.77

Indecisive


Highs/Lows of Iterum Therapeutics PLC
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.35 11.11 % 0.513 % 1.51.2331-May-2428-May-24
Two Week1.41 6.38 % 0.486 % 1.51.2331-May-2428-May-24
One Month1.53 1.96 % 4.80 % 1.661.2313-May-2428-May-24
Three Month1.24 20.97 % 3.56 % 1.931.2204-Apr-2401-Mar-24
Six Months1.88 20.21 % 15.54 % 2.341.219730-Jan-2423-Feb-24
One year1.15 30.43 % 26.26 % 2.50.62227-Nov-2325-Oct-23
Two year3.45 56.52 % 27.72 % 2.50.60127-Nov-2327-Dec-22
Five year93.9 98.40 % 91.77 % 3.13050.60118-Aug-2227-Dec-22


Technical View of Iterum Therapeutics PLC
RSI

53.13

Neutral
MACD

-0.052

Bearish
ADX

20.53

Bullish
Super Trend

1.59

Strong Bearish
Williams %R

-37.21

Mild Bullish
CCI

-17.20

Mild Bullish


EMA 5

1.38

Strong Bullish
EMA 15

1.42

Strong Bullish
EMA 50

1.50

Strong Bullish
EMA 100

1.50

Bearish
SMA 100

1.57

Mild Bearish
SMA 200

1.36

Neutral
SMA 5 / 20

1.35 / 1.46

Strong Bearish
SMA 15 / 50

1.42 / 1.54

Strong Bearish
SMA 50 / 200

1.54 / 1.36

Bullish




Charts of Iterum Therapeutics PLC


Returns of Iterum Therapeutics PLC with Peers
Period / StockITRMMTCRBSGMLSTA
1 Week11.11%2.18%16.18%-0.676%
1 Mth-1.96%2.43%21.08%7.69%
3 Mth20.97%2.41%193.00%0.341%
6mth-20.21%39.42%-22.78%34.25%
1 Year30.43%23.70%-87.03%-28.29%
2 Year-56.52%-85.36%-79.64%-61.19%
5 Years-98.40%--97.36%-93.26%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Iterum Therapeutics PLC with Peers
Ratio / StockITRMMTCRBSGMLSTA
PE-136.84-0.644-263.93-1.20
P/B1435.080.536-8574.020.458
ROA-91.35-58.14-867.76-34.61
ROE-1048.72-83.210-38.12
Debt To Equity-3.020.246-0.1160.0035
Revenue0
% 		0
% 		141000
50.70 % 		0
100.00 %
Net Income-31099.00 K
30.01 % 		-62207.00 K
66.76 % 		-29950.00 K
9.82 % 		-21465.00 K
60.41 %


Technicals of Iterum Therapeutics PLC with Peers
Technical / StockITRMMTCRBSGMLSTA-
ADX20.5314.3240.4511.83
CMF-0.03380.565-0.0337-0.136
MFI30.5686.6281.1168.02
RSI53.1357.1258.7750.24
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseTrueTrueTrue-
Price Above 200 MATrueTrueFalseTrue-


About : Iterum Therapeutics PLC

Address : Fitzwilliam Court, Dublin, Ireland, D02 YW24
Tel : 353 1 669 4820
URL : https://www.iterumtx.com
Code : ITRM, ISIN : IE00BF3W0Q35, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 25_May_2018
Employee Count : 14

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.


Note : All Data Generated at the End of Trading Hours (EOD Data)